Lapatinib Completed Phase 1 / 2 Trials for Cancer, Breast Treatment

Indications	Status	Purpose	Phase
DBCOND0054116 (Cancer, Breast)	Completed	Treatment	1 / 2

clinicaltrials.gov Identifier	Title	Drugs
NCT01133912	Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)	DB01259 (Lapatinib) DB00441 (Gemcitabine) DB01229 (Paclitaxel)
NCT00632489	LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients	DB01259 (Lapatinib) DB06603 (Panobinostat) DB01101 (Capecitabine)
NCT00085020	GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu	DB01259 (Lapatinib) DB00072 (Trastuzumab)
NCT00513058	Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer	DB00361 (Vinorelbine) DB01259 (Lapatinib)
NCT00379509	Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer	DB01259 (Lapatinib)
NCT00753207	Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30	DB01259 (Lapatinib) DB00445 (Epirubicin)
NCT00316875	Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer	DB01259 (Lapatinib) DB00997 (Doxorubicin)